Skip to main content
Premium Trial:

Request an Annual Quote

Tm Bioscience's Losses Mount But Revenues Gain as Firm Considers Strategic Options

NEW YORK (GenomeWeb News) — Tm Bioscience today said third-quarter revenues increased 19 percent as R&D spending rose 98 percent and loss increased 83 percent.
 
Total receipts for the three months ended Sept. 30 increased to $2.6 million from $2.2 million year over year.
 
Tm said $2.3 million of its sales came from its Tag-It reagents, and $300,000 came from instrument sales, an increase of 50 percent from a year ago.  
 
R&D spending increased to $1.3 million from $662,000 year over year.
 
The company said loss increased to $5.6 million from $3.1 million in the year-ago period.
 
Tm said it had around $4.7 million in cash and equivalents and $35,000 in short-term investments as of Sept. 30.
 
Earlier this week, Tm said it had formed a committee to consider merger or acquisition opportunities. In its financial statement Tm said it “continues to explore other sources of capital but believes that a strategic transaction provides the most cost effective source at this time,” but added that “no decision has been made to enter into any transaction at this time.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.